Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT04631744 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Prostate Cancer

Interventions

DRUG: Cabozantinib

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]